Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment (SPINART)

Bayer

Status and phase: Completed; Phase 3

Conditions: Hemophilia A

Treatments: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00623480

12800

2008-000985-21 (EudraCT Number)

Details and patient eligibility

About

To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.

Enrollment: 84 patients

Sex: Male

Ages: 12 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males aged 12 to 50 years (US and Argentina)

• Males aged 18 to 50 years (other countries)

• Subjects with severe hemophilia A (<1% FVIII:C) as confirmed by the central lab from a sample obtained at least 96 hours after FVIII administration wash-out. Allow for the inclusion of a maximum of 10% (n=8) of patients with 1-2% FVIII:C baseline levels as long as they exhibit clinical severity and comply with all other inclusion criteria.

• Subjects with at least 150 prior exposure days with any FVIII

• Subjects who have been on episodic treatment and no known regular prophylaxis treatment for more than 12 consecutive months in the previous 5 years

• Subjects with 6 to 24 bleeding events and/or treatments in the previous 6 months prior to study entry which are documented and available in the subjects medical records. Documentation can include records from previous physicians, specific home treatment records, emergency room or hospital records, x-ray reports, etc. The investigator can also document with a detailed note the number of bleeds reported by the subject in the last 6 months.

• Subjects with inhibitor formation surveillance (inhibitor or recovery testing) over the ten years prior to enrollment documented by the investigator and who do not have a history of any of the following:

  • A positive inhibitor titer of 5.0 Bethesda Unit (BU) or greater by either BU assay system at any time since first exposure to exogenous factor VIII
  • A positive inhibitor test result of 1.0 or greater performed by the original BU assay at any time in the past 10 years (A subject can have more than one positive inhibitor test of 0.6 or greater by the original BU assay test but all must be less than 1.0 BU using the original BU assay.)
  • A positive inhibitor test result of 0.6 or greater performed by the Nijmegen method at any time in the past 10 years

• Subjects with no inhibitor activity by Nijmegen-modified Bethesda assay, either positive (> 0.6 BU is considered positive) or borderline (> 0.3 and < 0.6 BU is considered borderline) as measured in the current study reference laboratory

Exclusion criteria

• Subjects with any other bleeding disease besides hemophilia A (i.e. von Willebrand disease)
• Subjects with thrombocytopenia (platelets < 100,000/mm3)
• Subjects with abnormal renal function (Cockcroft-Gault Creatinine Clearance value of 60 mL/min or lower)
• Subjects with active hepatic disease (Aspartate aminotransferase [AST] or Alanine aminotransferase [ALT] > 5xUpper Limit of Normal (ULN))
• Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study (the following drugs are however allowed: interferon-a treatment for Hepatitis C virus (HCV), Highly active anti-retroviral therapy (HAART) therapy for human immunodeficiency virus (HIV) and/or a total of two courses of pulse treatment with steroids for a maximum of 7 days at 1mg/kg or less)
• Subjects with an absolute CD4 lymphocyte cell count < 200 cells/mm3 (due to HIV, HCV or another suspected medical condition)
• Subjects with known hypersensitivity to rFVIII, mouse or hamster proteins
• Subjects who are receiving or had received other experimental drugs within 1 month prior to study entry
• Subjects who require any pre-medication to tolerate FVIII injections (e.g. anti-histamines)
• Subjects who are unwilling to comply with study visits or either of the possible treatment regimens
• Subjects who have a planned orthopedic intervention to be performed during the study that may substantially affect bleeding (e.g. surgical or chemical or radiological synovectomy)
• Subjects who are not suitable for participation in this study for any reason, according to the Investigator
• Subjects who have poor joint status as defined by routine need for a wheelchair or unable to ambulate without the assistance of a brace, cane or crutches
• Three or more joints that are already fused or "frozen" also called ankylosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

84 participants in 2 patient groups

Recombinant Factor VIII prophylaxis treatment

Experimental group

Description:

Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.

Treatment:

Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Recombinant Factor VIII on-demand treatment

Experimental group

Description:

Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.

Treatment:

Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)